(Q24234365)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21901702%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

0 references

1 reference

title

Interventions for latent autoimmune diabetes (LADA) in adults (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21901702%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21901702%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Huw Brunt

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21901702%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Helen Davies

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21901702%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Sopna Mannan

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21901702%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Rhys Williams

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21901702%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

7 September 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21901702%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

12 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21901702%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21901702%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

CD006165

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21901702%20AND%20SRC:MED&resulttype=core&format=json

Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes

12 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Slowly progressing type 1 diabetes: persistence of islet cell autoantibodies is related to glibenclamide treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

The role of sulphonylurea in combination therapy assessed in a trial of sulphonylurea withdrawal. Scandinavian Insulin-Sulphonylurea Study Group Research Team.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (LADA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Multicenter prevention trial of slowly progressive type 1 diabetes with small dose of insulin (the Tokyo study): preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

β-cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment: a 3-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Rosiglitazone preserves islet beta-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Lack of effect of intermittently administered sodium fusidate in patients with newly diagnosed type 1 diabetes mellitus: the FUSIDM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Autoimmune diabetes in adults: lessons from the UKPDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Effects of a short prednisone regime at clinical onset of type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Complete long-term recovery of beta-cell function in autoimmune type 1 diabetes after insulin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Diabetes classification: grey zones, sound and smoke: Action LADA 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Islet cell and glutamic acid decarboxylase antibodies present at diagnosis of diabetes predict the need for insulin treatment. A cohort study in young adults whose disease was initially labeled as type 2 or unclassifiable diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Influence of insulin treatment on insulin sensitivity in insulin requiring type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Anti-thyroid peroxidase antibody, IA-2 antibody, and fasting C-peptide levels predict beta cell failure in patients with latent autoimmune diabetes in adults (LADA)--a 5-year follow-up of the Ehime study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Peptide-based treatment for autoimmune diseases: learning how to handle a double-edged sword

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Insulin versus a combination of insulin and sulfonylurea in the treatment of NIDDM patients with secondary oral failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Non-obese adult onset diabetes with oral hypoglycemic agent failure: islet cell autoantibodies or reversible beta cell refractoriness?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Latent autoimmune diabetes in adults: definition, prevalence, beta-cell function, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

The islet autoantibody titres: their clinical relevance in latent autoimmune diabetes in adults (LADA) and the classification of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Effects of nicotinamide and intravenous insulin therapy in newly diagnosed type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Latent autoimmune diabetes of adulthood (LADA): an often misdiagnosed type of diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: implications for human type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Diabetes Antibody Standardization Program: First Assay Proficiency Evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Meglitinide analogues for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

A Coefficient of Agreement for Nominal Scales

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

The case of the misleading funnel plot

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Clinical review: Type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Forest plots: trying to see the wood and the trees

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Latent autoimmune diabetes of adulthood. Unique features that distinguish it from types 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Latent autoimmune diabetes in adults (LADA)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Latent Autoimmune Diabetes in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Etiological investigation of diabetes in young adults presenting with apparent type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Cochrane Database of Systematic Reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Progress in the characterization of slowly progressive autoimmune diabetes in adult patients (LADA or type 1.5 diabetes).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Investigating and Dealing with Publication and Other Biases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Clinical, autoimmune, and genetic characteristics of adult-onset diabetic patients with GAD autoantibodies in Japan (Ehime Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

The preliminary report from the nation-wide prevention study for type 1 diabetes initially diagnosed as type 2 in Japan

21 January 2018

1 reference

12 December 2020

Beta cell rest and recovery--does it bring patients with latent autoimmune diabetes in adults to euglycemia?

1 reference

12 December 2020

Insulin intervention to preserve beta cells in slowly progressive insulin-dependent (type 1) diabetes mellitus

1 reference

12 December 2020

[Autoantibodies against islet cell antigens and type 1 diabetes after treatment with interferon-alpha]

1 reference

12 December 2020

Study on improvement of islet beta cell function in patients with latent autoimmune diabetes mellitus in adults by integrative Chinese and Western medicine

1 reference

12 December 2020

Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes

1 reference

12 December 2020

Metformin monotherapy for type 2 diabetes mellitus

1 reference

12 December 2020

Latent autoimmune diabetes in adults: a guide for the perplexed

1 reference

12 December 2020

Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

1 reference

12 December 2020

Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials

1 reference

12 December 2020

GAD65 autoantibody epitopes in adult patients with latent autoimmune diabetes following GAD65 vaccination

1 reference

12 December 2020

[Detection of LADA-type diabetes in overweight diabetic patients. Is treatment with metformin suitable?]

1 reference

12 December 2020

Latent autoimmune diabetes in adults (LADA): usefulness of anti-GAD antibody titers and benefit of early insulinization

1 reference

12 December 2020

GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77

1 reference

12 December 2020

Follow-up of cyclosporin A treatment in type 1 (insulin-dependent) diabetes mellitus: lack of long-term effects

1 reference

12 December 2020

Latent autoimmune diabetes in adults (LADA) in South Wales: incidence and characterisation

1 reference

12 December 2020

[Effect of Tangyikang in improving the function of pancreatic islet beta cells in patients with latent autoimmune diabetes mellitus in adults].

1 reference

12 December 2020

Experience of the introduction of routine antibody testing in primary care and of running a trial for latent autoimmune diabetes in adults (LADA)

1 reference

12 December 2020

Prednisone administration in recent onset type I diabetes

1 reference

12 December 2020

Intensive therapy in adult insulin-dependent diabetes mellitus is associated with improved insulin sensitivity and reserve: a randomized, controlled, prospective study over 5 years in newly diagnosed patients

1 reference

12 December 2020

Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group

1 reference

12 December 2020

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.

1 reference

12 December 2020

UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB3

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/14651858.CD006165.PUB3

2 references

Consolidated OpenCitations Corpus – April 2017

457423

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21901702%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

457423

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21901702%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

PubMed publication ID

21901702

2 references

Consolidated OpenCitations Corpus – April 2017

457423